Gustave Roussy Transfert team members​

• CEO
  Fabrice Barlesi
• Executive director
  Christophe Javaud 
• Business developers
  Jérôme Gaborit
  Pierre Gandille
• Patent engineer / Responsable propriété intellectuelle
  Frédérique Le Bellego
• Patent engineer
  Sacha Cataldo
• Chargée de mission Accords et licences / Responsable gestion financière
  Daphné Descarpentries

From Innovation to the Patient

In 2000, Gustave Roussy established its subsidiary devoted to development: Gustave Roussy Transfert.
The Institute is the majority shareholder in this limited liability company with a capital of 200,200 euros, which is intended to :

Epidemiology of cancer

The epidemiology of cancer is the study of the prevalence of disease in human populations and variations in that prevalence resulting from a variety of factors including the environment, life style and genetic characteristics. The Epidemiology Unit at Gustave Roussy is within the Gustave Roussy Biostatistics and Epidemiology Department. 

The Pharmacovigilance Unit (UFPV) of the Clinical Research Division of Gustave Roussy performs real-time assessment of the safety of the investigational medicinal products used in nearly 90 clinical trials sponsored by Gustave Roussy or by other academic sponsors, in particular, from the Ile-de-France region (within the framework of GIRCI*). Constant attention is paid to monitoring the safety of investigational medicinal products with regard to potential side effects in patients. This is called pharmacovigilance for clinical trials.

Lab members

Direction:

• Director: Gianluca Severi (Inserm DR2)
• Co-directors: Alexis Elbaz (Inserm DR2) – Pascal Guenel (Inserm DR2)
• Operational manager: Pascale Gerbouin-Rérolle

Research Axis:

Publications

By October 2022, data from the E3N-E4N cohort have contributed to the publication of more than 250 scientific papers.

Here is a selection of 20 recent key papers published by the Exposome and Heredity team (post 2010):

Exposome, Inheritance, Cancer and Health

This group belongs to the UMR 1018/CESP - Centre de recherche en épidémiologie et en santé des populations

Lab members

• Aba Naila Myriam
  Epidemiologist
• Allodji Rodrigue
  Biostatistician
• Bejarano Quisoboni Daniel    
  Epidemiologist
• Belhout Amel    
  Clinical research associate
• Boumaraf Amel    
  Clinical research associate
• Chappat Juliette    
  Biostatistician
• Chounta Stefania    
  Epidemiologist
• De Vathaire Florent    
  Epidemiologist
• Demoor Charlotte    
  Epidemiologist
• Ducos Claire    
  Epidemiologist
• Fresneau Brice    
  Epidemiologist

Major publications

1. Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis. Allodji RS, Tucker MA, Hawkins MM, Le Deley MC, Veres C, Weathers R, Howell R, Winter D, Haddy N, Rubino C, Diallo I, Little MP, Morton LM, de Vathaire F. Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33361. Online ahead of print. PMID: 33105035
    

Epidemiology of radiation

This team is part of UMR 1018/CESP - Centre for research in epidemiology and population health

The team focuses its work on the epidemiology of the effects of ionizing radiation on health, as well as all aspects of quality of life of  long term survivors from childhood cancers